Q3 2020 Sales Performance

Building a world class synthetic lethal pipeline and unit gsk December 2018 Announced the Tesaro acquisition July 2019 Announced headline results from PRIMA July 2020 ⚫ Announced the Broad Institute and Boston SL unit Exploring Zejula's potential in lung cancer • Platinum sensitivity is a surrogate predictive marker of response to PARPS in ovarian and pancreatic cancer Best-in-class potential given all-comers efficacy & blood-brain barrier penetration • • 1L Ph3 NSCLC study starting H2 2020 Study Population Stage Illb/IV NSCLC • SQ or NSQ • CR/PR/SD after induction with 4-6 cycles of platinum- containing chemotherapy + pembrolizumab • ECOG PS 0-1 • No activating mutations n=650 randomised 1:1 Zejula All continue on pembrolizumab for up to a total of 24 months or until PD Placebo To disease progression or study withdrawal Dual primary endpoints: - Progression Free Survival/ Overall Survival Key secondary endpoints: • Time to progression in CNS Expanding our synthetic lethal pipeline Investigating collateral lethality with GSK '715, our Type 1 PRMT inhibitor • Formed a strategic partnership with IDEAYA to explore three combinations: - MAT2A + GSK'715 -Pol Theta + Zejula -Werner Helicase + dostarlimab IDEAVA BIOSCIENCES World leading collaborations and a dedicated research unit • Created a dedicated synthetic lethal research unit in Boston Collaborating with the Broad Institute, UCSF and Berkeley (latter via the LGR) to create the world's leading functional genomics capability BROAD UCSF Berkeley INSTITUTE UNIVERSITY OF CALIFORNIA. 31

View entire presentation